ASCO 2022 Conference Coverage


 

ASCO 2022 on Sacituzumab Govitecan vs. Treatment of Physician’s Choice in Previously Treated mTNBC: Final Results From the Phase 3 ASCENT Study

657 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login